By Dr Subotheni Thavaneswaran

Conference Papers

Price TJ; Burge M; Chantrill L; Chua YJ; Horvath L; McLachlan S-A; Pavlakis N; Shapiro J; Thavaneswaran S; Tran B; Yip D; Tancock G, 2020, 'Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S1283 - S1283, presented at ESMO Asia Virtual Congress, ELECTR NETWORK, 20 November 2020 - 22 November 2020, http://dx.doi.org/10.1016/j.annonc.2020.10.127

Shapiro JD; Thavaneswaran S; Underhill C; Robledo KP; Karapetis CS; Day FL; Nott LM; Jefford M, 2017, 'Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.3572

Segelov E; Thavaneswaran S; Waring P; Desai J; Mann K; Elez E; Chantrill L; Pavlakis N; Nott L; Underhill C; Khasraw M; Wasan H; Ciardiello F; Jefford M; Joubert W; Haydon A; Karapetis C; Price T; Wilson K, 2015, 'The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.', in Eur J Cancer, Vienna, pp. S726 - S726, presented at European Cancer Congress, Vienna, 25 September 2015 - 29 September 2015

Back to profile page